Novo Owner’s CEO on Obesity Sales Boom, Catalent Deal
Novo Holdings CEO Kasim Kutay discusses the surge in income from obesity drug sales and offers an update on the Catalent deal and insight on the company’s deal strategy. #press
Discussion
No replies yet.